Background: Osteogenic sarcoma (OS) is a highly malignant tumor of the bone. There are few reports in the literature regarding determination of c-erb B-2 (HER-2/neu) expression in cases of OS and also the results are quite variable.
INTRODUCTION MATERIALS AND METHODS

Osteogenic sarcoma (OS) is the most frequent and
The present study was a retrospective study (1997 highly malignant bone tumor, seen during second 2003) in the Department of histopathology. A total and third decade of life. [1] Several oncogenes and of 49 cases of OS were retrieved from surgical tumor suppressor genes are reported to be involved pathology files. Clinical details of cases were in the oncogenesis of OS. Although survival rate reviewed for age, sex, clinical presentation, increased up to 60-70% within the last 20 years, pathological diagnosis and treatment. Out of these the problem of non-response to chemotherapy 49 cases, proper follow up data was available in remains. There are many factors thought to have only 20 cases. Only pretreatment tissues from the an influence on prognosis of OS, but their exact primary tumor were used, except for one case, role is still controversial. The overexpression of cwhich had recurrence. No metastases were erbB-2 (also called neu or HER2) proto-oncogene evaluated. The follow up data was collected from has been studied and correlated with poor survival the radiotherapy files of these cases and their total rate in various human tumors especially breast as well as disease free survival was noted. carcinomas . Little is known about the expression Histological sections were obtained from formalin of c-erbB-2 in sarcomas, [2] especially OS and only fixed paraffin embedded tissues. The sections were few reports are available in the literature, that to restained and all the cases were reviewed by a showing controversial results. Therefore, in the pathologist to confirm the diagnosis of OS. For present study, we studied 20 cases of OS for immunohistochemistry (IHC), a representative expression of c-erbB-2 (HER-2/neu) and correlated blocks with adequate viable tumor (avoiding areas the expression with the survival rate of patients. of necrosis) were chosen. Monoclonal antibody against c-erbB-2/HER-2/Neu Ab-12 (clone CB 11) was obtained from Neomarkers. 3-4 µm thick sections were cut from tissue blocks, placed on pretreated glass slides, dried at 37ºC overnight and then at 60ºC for 30 minutes. Sections were dewaxed and rehydrated through graded alcohols. Inhibition of endogenous peroxidase was done by treatment for 30 minutes with 3% hydrogen peroxide in methanol. After washing, blocking was done with normal serum and 4 rinses with buffer were given. The slides were placed in microwave for 3 cycles for 4 minutes each and then these were allowed to cool at room temperature for 90 minutes. The slides were incubated with primary antibody at room temperature for 90 minutes followed by washing (3 times for 5 minutes each).Then slides were incubated with secondary antibody for 30 minutes followed by Avidin-Biotin reagent for 30 minutes and then DAB (Diaminobenzidine). The sections were again placed in running tap water, dehydrated in a graded series of alcohols, cleared in 2 changes of xylene and mounted. 
RESULTS
In a total of 20 cases, the age ranged from 8 years to 38 years with male to female ratio of 3.2: 1. 13 cases were amputation specimens and 7 cases were biopsies from the tumors. All cases were high grade conventional OS [ Figure 1 ], except one case of telangiectatic variant of OS. Six cases on histopathology were rich in osteoclastic type of giant cells [ Figure 2 ]. The primary site of involvement was lower end of femur in 11 cases and proximal end of tibia in 5 cases. Other sites involved were maxilla, fibula, chest wall and sacrum (one case each). One case had lung metastasis at the time of presentation. Disease free survival in these 20 cases varied from one month to 3½ years.
Pleural effusion, lung metastasis, cervical and retroperitoneal lymphadenopathy and bone metastasis were seen in four, three, three and two cases, respectively. Complete 
(focal cytoplasmic positivity in 1-25% cells) in 5 cases, 2+ in 3 cases, 3+ in 3 cases and 4+ cytoplasmic positivity in 6 cases [ Figure 3 ]. Osteoclastic type giant cells also showed strong cytoplasmic positivity in all six cases. The expression of c-erbB-2 was correlated with the disease free survival time of patients of OS. The intensity of cytoplasmic staining of monoclonal antibody against c-erbB-2/HER-2/Neu Ab-12 (clone CB 11) did not correlate with survival rate of the patients, response to chemotherapy and metastasis as shown in [ Table 1 ]. Spearman rank correlation test was applied and p value calculated was 0.692, which was not significant.
DISCUSSION
Osteogenic sarcoma (OS) is the most frequent primary malignant bone tumor, exclusive of hematopoietic malignancy. It usually occurs in patients between 10 and 25 years of age. Most OS arising denovo are located in the metaphyseal area of the long bones, particularly, lower end of femur, the upper end of tibia and the upper end of the humerus. Metastasis occurs most commonly to lungs (98%), other bones (37%), pleura (33%), and heart (20%). [3] 5-year survival is approximately 50-70%. [4] Various prognostic factors are tumor size, response to chemotherapy, post chemotherapy tumor necrosis, serum elevation of alkaline phosphatase levels. Several oncogenes and tumor suppressor genes are reported to be involved in the oncogenesis of OS as c-myc, c-raf, c-myb, c-met, c-sis, c gli, RB and p53. [5] [6] [7] [8] [9] [10] Amplification of mdm-2 gene has been correlated with poor prognosis in OS. [11] c-erb B-2 (HER-2/neu) proto-oncogene is located on human chromosome 17 at q21. [12] It encodes a 185-kilo dalton trans membrane glycoprotein that shows significant structural similarity to epidermal growth factor receptor. [13] The neu differentiation factor (NDF) stimulates the kinase activity of erb B-2. It however does not directly interact with erbB-2. Instead it interacts with a heterodimer of erb B-2 and the related receptor such as erbB3 or erbB4. [14] Elevated expression of erbB-2 family members have been reported in a variety of human tumors, particularly breast carcinomas. In the majority of studies, erb B-2 (HER-2/neu) over expression was found to be correlated with decreased survival. [15] Most recent series failed to find any prognostic relation between HER-2/neu overexpression and disease outcome. Such conflicting results can be explained by the low patient number evaluated in some studies and different methods used to determine c-erbB-2 (HER-2/neu) status, including solid matrix-blotting, Immunohistochemistry (IHC), fluorescent in situ hybridization (FISH) and enzyme linked immunoadsorbent assay (ELISA). Immunohistochemistry (IHC) is a preferred method, as it can be performed easily on a routine basis and it is used to identify proteins expressed by fixed cells in paraffin embedded tissue sections. [16] Normal bone shows very little expression of c-erbB-2. [17] There are very few reports in the literature regarding determination of c-erbB-2 (HER-2/neu) expression in cases of OS and in these few reports also the results are quite variable. Onda [4] et al in 1996 studied expression of c-erbB-2 in the tumors of 26 patients with conventional OS by immunoblot analysis and confirmed by IHC studies (CB11 antibody). They documented c-erbB-2 expression in 11 of 26 OS cases (42%) and expression of c-erbB-2 was strongly correlated with early pulmonary metastasis and poor survival rate for the patients. They suggested that c-erbB-2 plays a significant role in aggressive tumor growth and in the promotion of metastatic potential in OS. Gorlick [18] et al in 1999 analyzed expression of c-erbB-2 (HER-2/neu) in 47 patients of OS by IHC methods. They documented high levels of HER-2/neu expression in 20/47 OS samples (42.6%). High levels of c-erbB-2 were seen in patients with metastatic disease at presentation and at the time of relapse. They suggested that HER-2/neu should be evaluated prospectively as a prognostic indicator.
Zhou and colleagues [19] reported a correlation between cytoplasmic staining of HER-2/neu and increased risk of pulmonary metastasis in OS. Maitra et al [20] in 2001, studied 18 high grade OS by IHC and FISH analysis. Overexpression of erb B-2 was not observed in their study.
Kilpatrick et al in 2001
[21] also studied expression of HER-2/ neu oncogene in 41 cases of OS by IHC method. Complete membranous positivity was not seen in any of these cases and cytoplasmic positivity was observed in most of the cases irrespective of their subtype/grade. The expression was not associated with response to preoperative chemotherapy or disease progression.
Although IHC staining appears to be the predominant method for determining HER-2/neu oncogene overexpression, the results may be substantially affected by technical issues, including fixation, duration and prolonged storage. Also, type and sensitivity of the antibodies also differ. In the present study, membranous positivity of the expression of osteosarcoma was not seen. Cytoplasmic positivity also was not seen to correlate with response to chemotherapy, metastasis and disease free survival. Therefore, we recommend more prospective studies with larger number of cases to establish the role of c-erbB-2, as an independent prognostic factor in human OS.
